Adenosine Receptor A3 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Adenosine Receptor A3 (ADORA3) – Pipeline Review, H1 2020’, provides in depth analysis on Adenosine Receptor A3 (ADORA3) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Gastrointestinal, Metabolic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Male Health, Oncology, Ophthalmology, Infectious Disease, Musculoskeletal Disorders, Respiratory and Women's Health under development targeting Adenosine Receptor A3 (ADORA3).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)

– The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects

– The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BioIntervene Inc

Can-Fite BioPharma Ltd

Future Medicine Co Ltd

Palo BioFarma SL

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Adenosine Receptor A3 (ADORA3) - Overview

Adenosine Receptor A3 (ADORA3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development

BioIntervene Inc

Can-Fite BioPharma Ltd

Future Medicine Co Ltd

Palo BioFarma SL

Adenosine Receptor A3 (ADORA3) - Drug Profiles

BIO-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-2698 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

namodenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-1650 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piclidenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmonary Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Autoimmune Disorders, Inflammation, Liver Cancer and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ADORA3 for Chronic Inflammation and Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adenosine Receptor A3 (ADORA3) - Dormant Products

Adenosine Receptor A3 (ADORA3) - Discontinued Products

Adenosine Receptor A3 (ADORA3) - Product Development Milestones

Featured News & Press Releases

Apr 14, 2020: Can Fite to conduct investor call to review positive phase II NASH data

Apr 13, 2020: Can Fite received approval for covid-19 clinical trial in Israel, patient enrollment and dosing to commence immediately

Apr 07, 2020: Can-Fite reports positive top line results from its phase II NASH study with Namodenoson

Mar 30, 2020: Can-Fite implements interim analysis for its phase III psoriasis trial with data expected Q4 2020

Mar 23, 2020: Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel

Mar 18, 2020: Can-Fite to participate in Digital Bio-Europe Spring Partnering Conference; looks to partner on co-development of Piclidenoson for coronavirus treatment

Mar 16, 2020: Can-Fite: Progress in compassionate use program treating advanced liver cancer patients with Namodenoson

Mar 11, 2020: Can-Fite: New pre-clinical studies demonstrate inhibition of fat cell expansion by Cannabis derived CBD

Mar 05, 2020: Can-Fite updates on clinical milestone for its Phase III rheumatoid arthritis study with Piclidenoson; drugs combating rheumatoid arthritis are currently introduced for the treatment of the Coronavirus

Mar 03, 2020: Can-Fite is filing drug safety update report showing positive safety result phase II study of Namodenoson

Mar 03, 2020: Can-Fite is filing drug safety update report showing positive safety result phase III study of piclidenoson

Feb 27, 2020: Pre-clinical studies demonstrate CBD’s robust anti-cancer effect against liver cancer; Can-Fite and Univo Pharmaceuticals expand Collaboration Agreement

Feb 24, 2020: Can Fite files patent for Namodenoson to overcome drug resistance to checkpoint inhibitors for oncology indications

Feb 18, 2020: Can-Fite granted patent allowance for its NASH drug Namodenoson in South Korea; results of its NASH Phase II study are expected this quarter

Feb 13, 2020: Can-Fite submits Liver Cancer phase III protocol and registration plan to EMA for Namodenoson

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by BioIntervene Inc, H1 2020

Pipeline by Can-Fite BioPharma Ltd, H1 2020

Pipeline by Future Medicine Co Ltd, H1 2020

Pipeline by Palo BioFarma SL, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports